Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 39, Issue 4, Pages 931-938Publisher
WILEY-BLACKWELL
DOI: 10.1002/eji.200839035
Keywords
Clec9A; C-type lectins; DC; Targeting; Vaccination
Categories
Funding
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
mAb that recognise various cell surface receptors have been used to deliver antigen to DC and thereby elicit immune responses. The encouraging data obtained in mouse models suggests that this immunisation strategy is efficient and could lead to clinical trials. We discuss a number of issues pertinent to this vaccination approach. These include which molecules are the best targets for delivering antigen to DC, which DC subtypes should be targeted, the types of immune responses to be generated and whether additional adjuvants are required. Finally, we discuss some progress towards targeting antigen to human DC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available